DrugPatentWatch Database Preview

Drugs in Development Information for CC-220

« Back to Dashboard

Summary for CC-220

US Patents	24
International Patents	200
US Patent Applications	53
WIPO Patent Applications	33
Japanese Patent Applications	0
Clinical Trial Progress	Phase 1 (2014-11-01)
Vendors	19

US Patents for CC-220

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
CC-220		Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies	Celgene Corporation (Summit, NJ)
CC-220		Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione	Celgene Corporation (Summit, NJ)
CC-220		Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast	Celgene Corporation (Summit, NJ)
CC-220		Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases	CELGENE CORPORATION (Summit, NJ)
CC-220		Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same	Celgene Corporation (Summit, NJ)
CC-220		3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus	Celgene Corporation (Summit, NJ)
CC-220		Apremilast for the treatment of a liver disease or a liver function abnormality	Celgene Corporation (Summit, NJ)

International Patents for CC-220

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
CC-220	Australia	2015305449	2034-08-22
CC-220	Brazil	112017003620	2034-08-22
CC-220	Canada	2958867	2034-08-22
CC-220	Chile	2017000416	2034-08-22
CC-220	China	107073115	2034-08-22
CC-220	Eurasian Patent Organization	201790439	2034-08-22
CC-220	European Patent Office	3182996	2034-08-22